{
    "nct_id": "NCT04513028",
    "official_title": "Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma",
    "inclusion_criteria": "* Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).\n* Must be treatment na√Øve or have had treatment no less than 6 months prior to enrollment\n* 18 years or older\n* Must be able to take pills\n* ECOG performance status of 0-3\n* Ability to understand and willingness to sign a written informed consent\n* Members of all racial and ethnic groups are eligible for this study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of hypersensitivity reactions attributed to beta-glucan\n* Patients receiving continuous or other ongoing immunosuppressive therapy\n* Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately\n* Patients with mucosal melanoma\n* Patients with concurrent malignancy or recent history thereof",
    "miscellaneous_criteria": ""
}